复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者疗效研究

doi:10.3969/j.issn.1672-5069.2021.01.019

摘要/Abstract

摘要： 目的探讨应用复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎(AH)伴胆汁淤积患者的疗效及对患者血清可溶性血管粘附分子 1(sVCAM 1)、磷脂转运蛋白(PLTP)和氧化应激指标的影响。方法 2018年5月~2019年7月我院消化内科收治的114例AH伴胆汁淤积患者,被随机分为对照组57例和观察组57例,分别给予丁二磺酸腺苷蛋氨酸或在此基础上联合应用复方甘草酸苷治疗4周。采用ELISA法检测血清sVCAM 1和PLTP水平,采用硫代巴比妥酸法检测血清丙二醛(MDA),采用比色法检测血清谷胱甘肽过氧化物酶(GST-Px)和采用邻苯三酚法检测血清超氧化物歧化酶(SOD)水平。结果在治疗结束时,观察组血清TBIL水平为(24.6±6.4)μmol/L,显著低于对照组【(47.6±12.4)μmol/L,P<0.05】,血清丙氨酸氨基转移酶(ALT)水平为(36.1±11.4)U/L,显著低于对照组【(47.6±12.4)U/L,P<0.05】,血清天冬氨酸氨基转移酶(AST)水平为(45.3±14.8)U/L,显著低于对照组【(75.9±19.5)U/L,P<0.05】,血清碱性磷酸酶(ALP)水平为(81.9±21.3)U/L,显著低于对照组【(122.3±35.8)U/L,P<0.05】;血清sVCAM 1水平为(453.3±31.8)ng/mL,显著低于对照组【(573.4±41.2)ng/mL,P<0.05】,血清PLTP水平为(3.6±0.4)pg/mL,显著低于对照组【(4.7±0.6)pg/mL,P<0.05】;血清MDA水平为(23.8±2.8)mmol/L,显著低于对照组【(28.6±2.7)mmol/L,P<0.05】,而血清GST-Px水平为(115.5±8.2)mmol/L,显著高于对照组【(106.7±8.1)mmol/L,P<0.05】,血清SOD水平为(186.3±10.6)U/L,显著高于对照组【(153.7±10.4)U/L,P<0.05】。结论应用复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者可降低血清sVCAM 1和PLTP水平,抑制机体氧化应激反应,改善和促进肝功能恢复,疗效确切。

关键词: 酒精性肝炎, 胆汁淤积, 复方甘草酸苷, 丁二磺酸腺苷蛋氨酸, 可溶性血管粘附分子 1, 磷脂转运蛋白, 氧化应激, 治疗

Abstract: Objective The aim of this study was to investigate the clinical efficacy of compound glycyrrhizin and adenosylmethionine succinate combination in treatment of patients with alcoholic hepatitis (AH) with cholestasis and its influences on serum soluble vascular adhesion molecule 1 (sVCAM 1), phospholipid transporter (PLTP) and oxidative stress parameters. Methods 114 patients with AH and hyperbilirubinemia were recruited in Department of Gastroenterology in our hospital, and were divided randomly into observation (n=57) and control group (n=57). The patients in control group was treated with intravenous adenosylmethionine succinate injection, and those in the observation group were treated with compound glycyrrhizin and adenosylmethionine combination for four weeks. Serum sVCAM 1, PLTP, malondialdehyde ( MDA), glutathione peroxidase (GST-Px) and superoxide dismutase (SOD) levels were detected. Results At the end of treatment, serum bilirubin level in the observation group was (24.6±6.4) μmol/L, which was significantly lower than in the control group, serum alanine aminotransferase level was (36.1±11.4) U/L, much lower than in the control group, serum aspartate aminotransferase level was (45.3±14.8) U/L, significantly lower than in the control, serum alkaline phosphatase level was (81.9±21.3) U/L, significantly lower than [(122.3±35.8) U/L in the control; serum sVCAM 1 level was (453.3±31.8) ng/mL, which was significantly lower than [(573.4±41.2) ng/mL, P<0.05] in the control, and serum PLTP level was (3.6±0.4) pg/mL, significantly lower than in the control; serum MDA level was (23.8±2.8) mmol/L, much lower than in the control, while serum GST-Px level was (115.5±8.2) mmol/L, which was significantly higher than and serum SOD level was (186.3±10.6) U/L, significantly higher than in the control.Conclusion The intravenous administration of compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis with intrahepatic cholestasis could improve liver function index normalization and subsiding jaundice, which might be related to the decreased serum sVCAM 1 and PLTP levels, and the inhibition of oxidative stress response, and warrants further investigation.

Key words: Alcoholic hepatitis, Cholestasis, Compound glycyrrhizin, Adenosylmethionine succinate, Soluble vascular adhesion molecule 1, Phospholipid transporter, Oxidative stress, Therapy

蔡宇, 王孟春, 邱新平, 张宁宁, 刘丽莉, 吴博, 杨奇. 复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 71-74.

Cai Yu, Wang Mengchun, Qiu Xinping, et al. Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis[J]. Journal of Practical Hepatology, 2021, 24(1): 71-74.

参考文献

[1] 孙红菊, 王衍颜, 徐丛聪, 等. 硫普罗宁联合美他多辛治疗酒精性肝病患者疗效初步研究. 实用肝脏病杂志, 2020, 23(1): 54-57.
[2] Vakhrushev YM, Lukashevich АР, Penkina IA, et al. Comparative analysis of bile acid spectrum in non-alcoholic fatty liver disease and cholelithiasis. Ter Arkh, 2019, 91(2): 48-51.
[3] Salavrakos M, Piessevaux H, Komuta M, et al. Fibroscan reliably rules out advanced liver fibrosis and significant portal hypertension in alcoholic patients. J Clin Gastroenterol, 2019, 53(10): 772-778.
[4] Ivashkin VT, Maevskaya MV, Kobalava ZD, et al. Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease. Minerva Gastroenterol Dietol, 2018, 64(3): 208-219.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2): 170-176.
[6] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015). 实用肝脏病杂志, 2016, 19(6): 771-781.
[7] Peeraphatdit TB, Simonetto DA, Shah VH. Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from nash and cholestasis. J Hepatol, 2018, 69(2): 275-277.
[8] Furuya S, Argemi J, Uehara T, et al. A novel mouse model of acute-on-chronic cholestatic alcoholic liver disease: a systems biology comparison with human alcoholic hepatitis. Alcohol Clin Exp Res, 2020, 44(1): 87-101.
[9] Blaya D, Coll M, Rodrigo-Torres D, et al. Integrative microrna profiling in alcoholic hepatitis reveals a role for microrna-182 in liver injury and inflammation. Gut, 2016, 65(9): 1535-1545.
[10] Beyolu D, Idle JR. Metabolomic and lipidomic biomarkers for premalignant liver disease diagnosis and therapy. Metabolites, 2020, 10(2): E50.
[11] Schulz M, Beha D, Plehm K, et al. High prevalence of anti-hepatitis e virus antibodies in outpatients with chronic liver disease in a university medical center in germany. Eur J Gastroenterol Hepatol, 2016, 28(12): 1431-1436.
[12] Yao M, Wang L, Leung PSC, et al. The clinical significance of gp73 in immunologically mediated chronic liver diseases: experimental data and literature review. Clin Rev Allergy Immunol, 2018, 54(2): 282-294.
[13] 池肇春. 肠道屏障功能障碍与酒精性肝病研究进展. 世界华人消化杂志, 2019, 27(19): 1179-1192.
[14] Salavrakos M, Piessevaux H, Komuta M, et al. Fibroscan reliably rules out advanced liver fibrosis and significant portal hypertension in alcoholic patients. J Clin Gastroenterol, 2019, 53(10): 772-778.
[15] Ezhilarasan D. Oxidative stress is bane in chronic liver diseases: clinical and experimental perspective. Arab J Gastroenterol, 2018, 19(2): 56-64.
[16] Haidari F, Hojhabrimanesh A, Helli B, et al. An energy-restricted high-protein diet supplemented with β -cryptoxanthin alleviated oxidative stress and inflammation in nonalcoholic fatty liver disease: a randomized controlled trial. Nutrit Res, 2020, 73(5): 13-15.
[17] Shipovskaya AA, Dudanova OP. Intrahepatic cholestasis in nonalcoholic fatty liver disease. Ter Arkh, 2018, 90(2): 69-74.
[18] 徐贝贝, 李银玲, 王炳元. 酒精性肝病相关危险因素的研究进展. 中华肝脏病杂志, 2017, 25(5): 397-400.
[19] Karimani A, Heidarpour M, Moghaddam Jafari A. Protective effects of glycyrrhizin on sub-chronic diazinon-induced biochemical, hematological alterations and oxidative stress indices in male Wistar rats. Drug Chem Toxicol, 2019, 42(3): 300-308.
[20] Wang Y, Chen Q, Shi C, et al. Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress. Mol Med Rep, 2019, 20(5): 4081-4090.
[21] Sun Y, Shao C, Qu H, et al. Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: a case report. Medicine (Baltimore), 2018, 97(37): e12395.